Judge Rules Discovery Will Be Limited to One Formulation of Lupron

TAMPA, Fla. - A federal judge ordered that discovery and depositions of Tap Pharmaceuticals' employees would be limited to the 3.75 mg dosage of Lupron Depot, which plaintiffs claimed caused them to suffer injuries. Katricia Arnett and Raymond Arnett, et al. v. Tap Pharmaceuticals Inc. No. 03-CV-304-T-26TBM (M.D. Fla., Tampa Div.).

In an order entered Dec. 4, 2003, U.S. District Judge Richard A. Lazzara denied without prejudice the plaintiffs' motion to compel the manufacturer to produce documents and have its employees answer questions regarding all formulations of the drug in depositions.

The five plaintiffs in the case claimed that they …